- Home
- DNTH vs EVLV Comparison
DNTH vs EVLV Comparison
Compare DNTH & EVLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- EVLV
- Stock Information
- Founded
- DNTH 2015
- EVLV 2013
- Country
- DNTH United States
- EVLV United States
- Employees
- DNTH N/A
- EVLV N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- EVLV Computer peripheral equipment
- Sector
- DNTH Health Care
- EVLV Technology
- Exchange
- DNTH Nasdaq
- EVLV Nasdaq
- Market Cap
- DNTH 565.7M
- EVLV 529.4M
- IPO Year
- DNTH N/A
- EVLV N/A
- Fundamental
- Price
- DNTH $19.50
- EVLV $3.31
- Analyst Decision
- DNTH Strong Buy
- EVLV Strong Buy
- Analyst Count
- DNTH 8
- EVLV 4
- Target Price
- DNTH $54.33
- EVLV $5.00
- AVG Volume (30 Days)
- DNTH 418.5K
- EVLV 1.4M
- Earning Date
- DNTH 05-08-2025
- EVLV 05-08-2025
- Dividend Yield
- DNTH N/A
- EVLV N/A
- EPS Growth
- DNTH N/A
- EVLV N/A
- EPS
- DNTH N/A
- EVLV N/A
- Revenue
- DNTH $6,235,000.00
- EVLV $89,220,000.00
- Revenue This Year
- DNTH N/A
- EVLV $28.98
- Revenue Next Year
- DNTH N/A
- EVLV $25.25
- P/E Ratio
- DNTH N/A
- EVLV N/A
- Revenue Growth
- DNTH 120.63
- EVLV 17.67
- 52 Week Low
- DNTH $13.37
- EVLV $2.01
- 52 Week High
- DNTH $32.27
- EVLV $4.65
- Technical
- Relative Strength Index (RSI)
- DNTH 53.31
- EVLV 53.16
- Support Level
- DNTH $18.37
- EVLV $2.91
- Resistance Level
- DNTH $19.76
- EVLV $3.54
- Average True Range (ATR)
- DNTH 1.93
- EVLV 0.25
- MACD
- DNTH 0.45
- EVLV 0.05
- Stochastic Oscillator
- DNTH 95.93
- EVLV 74.44
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About EVLV Evolv Technologies Holdings Inc.
Evolv Technologies Holdings Inc offers an AI-based touchless security screening. Its touchless security screening systems use artificial intelligence software, cloud services, and advanced sensors to reliably detect dangerous weapons while ignoring harmless items like cell phones, laptops, and keys. It offers products for purchase and primarily under a multi-year security-as-a-service subscription pricing model that delivers ongoing value to customers, generates predictable revenue, and creates expansion and upsell opportunities. The firm operates in a single segment that develops, manufactures, markets, and sells security screening products and specific services. Its products are used in different industries such as casinos, industrial workplaces, schools, and ticketed venues.